Dasatinib: Patient-Friendly Guide for Australian Patients
Basic Product Information
- International Non-Proprietary Name (INN): Dasatinib
- Australian Brand Names: Sprycel® (most common), generic Dasatinib available
- Anatomical Therapeutic Chemical (ATC) Code: L01EA02
- Available Forms & Strengths: Film-coated tablets in 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg strengths
- Manufacturers (Australia): Bristol-Myers Squibb Australia, Sandoz, and additional generic suppliers
- Prescription Status: Schedule 4 (Prescription Only Medicine), requires a doctor’s prescription
| Form | Strengths | Pack Sizes |
|---|---|---|
| Film-Coated Tablet | 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg | 30, 60 (varies by supplier/strength) |
Mechanism of Action
In simple terms: Dasatinib is a type of cancer medication known as a tyrosine kinase inhibitor (TKI). It works by blocking specific proteins called tyrosine kinases on the surface of cancer cells. By doing so, it helps slow down or stop the growth of certain blood cancers, such as leukaemia.
For specialists: Dasatinib inhibits BCR-ABL kinase activity and other kinases including SRC, c-KIT, ephrin (EPH), and PDGFR-β. It is highly effective against most BCR-ABL mutations (except T315I) and is a second-generation TKI with improved potency and breadth compared to imatinib.
Pharmacokinetics
- Absorption: Rapidly absorbed (peak plasma levels at 0.5–3 hours after oral dose)
- Bioavailability: Approx. 14–34% (variable, affected by gastric pH and food)
- Distribution: High volume of distribution; extensively bound to plasma proteins (96%)
- Metabolism: Predominantly hepatic via CYP3A4 enzyme, with minor contributions from CYP2C8, CYP2D6, and CYP3A5
- Elimination: Mainly excreted in faeces (85%), minimal via urine (4%); mean half-life 3–5 hours
- Duration of Action: Requires daily dosing due to relatively short half-life
Use in Everyday Life and Best Practices
Dasatinib is used primarily to treat adults and children with:
- Chronic myeloid leukaemia (CML; Ph+)
- Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL)
- Other rare indications as directed by a specialist
How to Take Dasatinib
- Take at the same time each day to maintain steady levels.
- Swallow tablets whole, with a full glass of water.
- Do not take with grapefruit, grapefruit juice, or any supplements/foods that may interfere with absorption.
- Do not double up if a dose is missed—take the next dose as scheduled.
- If you experience severe side effects (difficulty breathing, chest pain, swelling, severe skin reactions), contact your doctor immediately.
Your doctor or pharmacist will give you personalised instructions based on your current health and other medicines you may be taking.
Dosing in the Morning vs Evening
- Morning Use: May reduce risk of stomach upset for some individuals, minimises chance of interfering with sleep if you experience side effects such as fatigue or gastrointestinal symptoms.
- Evening Use: May suit those with a morning routine that makes medication adherence difficult in the morning. Monitor for any impact on sleep due to potential side effects (e.g., headache, restless sleep).
- Tips: Pick a consistent time that best fits your daily schedule to help with compliance—using a daily alarm/reminder can be helpful.
Taking with Food or on an Empty Stomach
- Dasatinib can be taken with or without food.
- Avoid taking with high-fat meals, which may increase the risk of side effects.
- Do not take with or soon after eating grapefruit or drinking grapefruit juice, as this may change medicine levels in your body and increase side effects.
- Follow a healthy, varied Australian diet as recommended by your healthcare team.
- Wholemeal breads, fresh fruit (apart from grapefruit), and lean meats are safe and compatible with your treatment.
Interaction Warnings
| Type of Interaction | Examples | Advice |
|---|---|---|
| Food | Grapefruit, grapefruit juice | Avoid, as it increases risk of side effects |
| Alcohol | All types | Limit/avoid; can worsen side effects and impair liver function |
| Medications |
| Check with your doctor or pharmacist before use. Some can lower effectiveness or cause side effects. |
| Vaccines | Live vaccines (MMR, oral polio, yellow fever, BCG) | Do not use live vaccines during treatment. |
Indications
| Indication | Status in Australia | Notes |
|---|---|---|
| Chronic Myeloid Leukaemia (CML, Ph+) | Approved | Adults and children; newly diagnosed or after other TKI therapy |
| Philadelphia Chromosome–Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) | Approved | Adults and children; when other therapies are unsuitable |
| Other BCR-ABL positive leukaemias | Specialist use/off-label | Assessed case by case |
Dosing According to Clinical Indication
| Indication | Adults (≥18 yrs) | Children/Adolescents | Elderly |
|---|---|---|---|
| Chronic Myeloid Leukaemia (CML) | 100 mg once daily (chronic phase); 140 mg once daily (accelerated/blast phase) | 60 mg/m2 once daily (chronic/accelerated phase); max 100 mg | Monitor more frequently for side effects, same starting dose; dose reductions as needed |
| Ph+ Acute Lymphoblastic Leukaemia (ALL) | 140 mg once daily | 60 mg/m2 once daily; max 120 mg | As above; lower doses may be required for kidney or hepatic impairment |
Note: Always follow your doctor’s advice as individual doses may be adjusted based on response, blood tests, and specific health needs.
Safety Profile and Side Effects
| Frequency | Side Effect | Notes |
|---|---|---|
| Very Common (>10%) | Fluid retention/swelling, low blood cell counts (anaemia, neutropenia), infections, headache, diarrhoea, nausea, skin rash | Report persistent symptoms to your doctor |
| Common (1–10%) | Fatigue, shortness of breath, muscle pain, fever, increased liver enzymes | May require dose adjustment or supportive treatment |
| Uncommon/Rare (<1%) | Pulmonary arterial hypertension, severe allergic reactions, heart rhythm problems | Seek urgent medical attention for severe chest pain, difficulty breathing, allergic signs |
- Most side effects are mild-to-moderate and manageable with your healthcare team’s support.
- Regular blood tests will be needed to monitor for low blood counts, liver function, and other safety markers.
- Contact your doctor immediately if you notice unusual bleeding, severe shortness of breath, or signs of infection.
Guidelines for Proper Use (Australian Conditions)
- Store Dasatinib at room temperature (below 30°C), away from direct sunlight and moisture.
- Keep all medicine out of reach of children and pets, ideally in a locked cabinet.
- Participate in regular check-ups (blood tests and doctor visits) as recommended by your specialist.
- Discuss all other medicines and over-the-counter supplements with your healthcare team.
- Travel: Carry a copy of your prescription and keep tablets in the original packaging when travelling within Australia or overseas.
- Do not stop taking Dasatinib unless your doctor says it is safe to do so, even if you feel well.
- Australian summer: Stay hydrated, and let your doctor know if you become unwell with fever or infection.
Alternative Treatment Options
- Imatinib (Glivec®): First-generation TKI, available on PBS. Pros: Good track record, oral tablets, well-studied. Cons: May not work for everyone, resistance possible.
- Nilotinib (Tasigna®): Second-generation TKI. Pros: More potent than Imatinib. Cons: May have more strict dietary restrictions, cardiovascular warnings.
- Bosutinib (Bosulif®): Another option on PBS. Pros: Active against some resistant cases. Cons: May be less suitable with liver disease.
- Allogeneic stem cell transplantation: Only for select cases or when other therapies fail; has significant risks and higher cost.
Your haematologist will guide you on which option is best suited to your condition, taking into account PBS funding, effectiveness, side effects, and your personal circumstances.
Legal, Registration, and Reimbursement Status in Australia
- Registered by the Therapeutic Goods Administration (TGA), Australia
- Prescription required from a medical practitioner
- Reimbursed under the Pharmaceutical Benefits Scheme (PBS) for eligible indications—consult your doctor for tailored access
- Patient support programs are available from some manufacturers to help manage costs
- Private insurance may cover costs not met by PBS; check with your insurer
Latest Research and Clinical Guidance (2022–2025)
- Recent Australian and international studies (Lancet Haematology 2023; Blood Adv 2024) confirm Dasatinib’s high efficacy and safety in managing CML and Ph+ ALL, both frontline and after previous TKI failure.
- Current guidelines (EHA/ELN 2023–2024, Cancer Council Australia) recommend Dasatinib as a standard-of-care for Philadelphia chromosome–positive CML and ALL, including in paediatric cases.
- Emerging research suggests intermittent dosing or treatment discontinuation may be possible in some patients achieving deep, stable molecular remission, but this must be done under strict specialist supervision.
- The use of Dasatinib in combination with other therapies is being assessed in clinical trials for improved outcomes in high-risk or resistant disease.
- Contact your specialist about participation in approved clinical trials if standard therapy has not been effective.
Availability and Delivery
| Pack Size (tablets) | Indicative PBS Price (May 2024)* | Delivery (Metro) | Delivery (Regional/Remote) |
|---|---|---|---|
| 30 | $41 (patient co-payment) | 1–2 working days (Sydney, Melbourne, Brisbane, Canberra, Adelaide, Perth) | 3–5 working days (Darwin, Townsville, Alice Springs, Broome, Hobart, regional NSW/WA/QLD/SA/VIC) |
| 60 | $41 (patient co-payment) | 1–2 working days (see above) | 3–5 working days (see above) |
*Prices shown are patient co-payment under PBS for general patients. Concession Card holders pay less (typically $7.30/package). For private prescriptions, actual prices may vary—please check with your local pharmacy for up-to-date costs and supply details.
FAQ – Common Patient Questions About Dasatinib
- Can I stop Dasatinib if my leukaemia is in remission?
No. Only stop or change your dose upon your specialist’s advice. Some patients in sustained deep remission can consider stopping therapy under very close monitoring, but this must be guided by your haematologist and regular blood tests.
- What should I do if I miss a dose?
If it is within a few hours of your usual dose time, take it as soon as you remember. If it is nearly time for your next dose, skip the missed dose—do not double up. Always try to take your medicine at the same time every day.
- Can I eat out or travel while taking Dasatinib?
Yes, but avoid grapefruit and certain prescription medicines. Inform travel insurance and airport security about your prescription. Carry your medicine in its original packaging and keep your prescription handy when flying or crossing borders.
- Are there any lifestyle restrictions while on Dasatinib?
No strict restrictions, but stay hydrated, eat a balanced diet, and avoid risky contact sports to reduce bleeding risk. Discuss vaccinations and other medicines with your doctor before starting.
- How will Dasatinib affect my blood tests?
Your doctor will closely monitor your blood counts, liver and kidney function during treatment. It's normal for some changes to happen but report any unexpected bleeding, bruising, or signs of infection immediately.
If you have further questions about Dasatinib, always ask your pharmacist, haematologist, or healthcare team. For urgent issues, contact your doctor or nearest emergency service (Healthdirect Australia).
